{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:27:59Z","timestamp":1791350879483,"version":"4.3.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T00:00:00Z","timestamp":1464134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s40262-016-0412-5","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T09:34:44Z","timestamp":1464168884000},"page":"1435-1445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Evaluation of Cytochrome P450 3A4-Mediated Drug\u2013Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation"],"prefix":"10.1007","volume":"55","author":[{"given":"Nageshwar R.","family":"Budha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Musib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Eppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Dresser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Y.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,25]]},"reference":[{"issue":"5","key":"412_CR1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1021\/ml300049d","volume":"3","author":"KD Rice","year":"2012","unstructured":"Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, et al. Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973). ACS Med Chem Lett. 2012;3(5):416\u201321.","journal-title":"ACS Med Chem Lett."},{"issue":"1","key":"412_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"412_CR3","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291\u2013310.","journal-title":"Oncogene"},{"issue":"20","key":"412_CR4","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867\u201376.","journal-title":"N Engl J Med"},{"key":"412_CR5","unstructured":"US Food and Drug Administration. Cobimetinib (Cotellic) presecribing information. Silver Spring: US Food and Drug Administration; 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206192s000lbl.pdf ."},{"key":"412_CR6","unstructured":"US Food and Drug Administration. Cobimetinib (COTELLIC) clinical pharmacology and biopharmaceutics review: summary basis of approval. Silver Spring: US Food and Drug Administration; 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206192Orig1s000ClinPharmR.pdf . Accessed 5 May 2016."},{"issue":"5","key":"412_CR7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1124\/dmd.111.043778","volume":"40","author":"EF Choo","year":"2012","unstructured":"Choo EF, Belvin M, Boggs J, Deng Y, Hoeflich KP, Ly J, et al. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions. Drug Metab Dispos. 2012;40(5):919\u201327.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"412_CR8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/clpt.2010.298","volume":"89","author":"P Zhao","year":"2011","unstructured":"Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89(2):259\u201367.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"412_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/bdd.1776","volume":"33","author":"A Rostami-Hodjegan","year":"2012","unstructured":"Rostami-Hodjegan A, Tamai I, Pang KS. Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay! Biopharm Drug Dispos. 2012;33(2):47\u201350.","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"412_CR10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd2173","volume":"6","author":"A Rostami-Hodjegan","year":"2007","unstructured":"Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov. 2007;6(2):140\u20138.","journal-title":"Nat Rev Drug Discov."},{"key":"412_CR11","unstructured":"European Medicines Agency (EMA)\u2014Committee for Human Medicinal Products (CHMP). Guideline on the investigation of drug interactions. London: EMA; 2013."},{"key":"412_CR12","volume-title":"Guidance for industry: drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations (Draft Guidance)","author":"US Food and Drug Administration","year":"2012","unstructured":"US Food and Drug Administration. Guidance for industry: drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations (Draft Guidance). Rockville: US Department of Health and Human Services; 2012."},{"key":"412_CR13","volume-title":"Ibrutinib (IMBRUCIVIA) prescribing information","author":"US Food and Drug Administration","year":"2015","unstructured":"US Food and Drug Administration. Ibrutinib (IMBRUCIVIA) prescribing information. Sunnyvale: Phamacyclics, Inc.; 2015."},{"issue":"11","key":"412_CR14","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1021\/mp400383x","volume":"10","author":"L Musib","year":"2013","unstructured":"Musib L, Choo E, Deng Y, Eppler S, Rooney I, Chan IT, et al. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. Mol Pharm. 2013;10(11):4046\u201354.","journal-title":"Mol Pharm"},{"issue":"5","key":"412_CR15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","volume":"55","author":"KT Olkkola","year":"1994","unstructured":"Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;55(5):481\u20135.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"412_CR16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1124\/dmd.115.066282","volume":"44","author":"RH Takahashi","year":"2016","unstructured":"Takahashi RH, Choo EF, Ma S, Wong S, Halladay J, Deng Y, et al. Absorption, metabolism, excretion, and the contribution of intestinal metabolism to the oral disposition of [14C]cobimetinib, a MEK inhibitor, in humans. Drug Metab Dispos. 2016;44(1):28\u201339.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"412_CR17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2125.2010.03883.x","volume":"71","author":"D Rekic","year":"2011","unstructured":"Rekic D, Roshammar D, Mukonzo J, Ashton M. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol. 2011;71(4):536\u201343.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"412_CR18","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1124\/dmd.113.051755","volume":"41","author":"C Xu","year":"2013","unstructured":"Xu C, Quinney SK, Guo Y, Hall SD, Li L, Desta Z. CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug Metab Dispos. 2013;41(12):2004\u201311.","journal-title":"Drug Metab Dispos"},{"issue":"3\u20134","key":"412_CR19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10928-005-0026-2","volume":"32","author":"TH Waterhouse","year":"2005","unstructured":"Waterhouse TH, Redmann S, Duffull SB, Eccleston JA. Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. J Pharmacokinet Pharmacodyn. 2005;32(3\u20134):521\u201345.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"412_CR20","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1021\/mp4003249","volume":"10","author":"N Fotaki","year":"2013","unstructured":"Fotaki N, Klein S. Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data. Mol Pharm. 2013;10(11):4016\u201323.","journal-title":"Mol Pharm"},{"issue":"Suppl 1","key":"412_CR21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","volume":"32","author":"J Heykants","year":"1989","unstructured":"Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32(Suppl 1):67\u201387.","journal-title":"Mycoses"},{"issue":"5","key":"412_CR22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/clpt.2014.41","volume":"95","author":"AB Ke","year":"2014","unstructured":"Ke AB, Zamek-Gliszczynski MJ, Higgins JW, Hall SD. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther. 2014;95(5):473\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"412_CR23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/bdd.1992","volume":"37","author":"I Templeton","year":"2015","unstructured":"Templeton I, Ravenstijn P, Sensenhauser C, Snoeys J. A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. Biopharm Drug Dispos. 2015;37(1):15\u201327.","journal-title":"Biopharm Drug Dispos"},{"issue":"10","key":"412_CR24","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1124\/dmd.115.064618","volume":"43","author":"S Yamazaki","year":"2015","unstructured":"Yamazaki S, Johnson TR, Smith BJ. Prediction of drug\u2013drug interactions with crizotinib as the CYP3A substrate using a physiologically based pharmacokinetic model. Drug Metab Dispos. 2015;43(10):1417\u201329.","journal-title":"Drug Metab Dispos"},{"key":"412_CR25","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1038\/psp.2014.49","volume":"3","author":"N Marsousi","year":"2014","unstructured":"Marsousi N, Daali Y, Rudaz S, Almond L, Humphries H, Desmeules J, et al. Prediction of metabolic interactions with oxycodone via CYP2D6 and CYP3A inhibition using a physiologically based pharmacokinetic model. CPT Pharmacometrics Syst Pharmacol. 2014;3:e152.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"2","key":"412_CR26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00228-013-1603-8","volume":"70","author":"A Nordmark","year":"2014","unstructured":"Nordmark A, Andersson A, Baranczewski P, Wanag E, Stahle L. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. Eur J Clin Pharmacol. 2014;70(2):167\u201378.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"412_CR27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1517\/17425255.2015.1034688","volume":"11","author":"J Chen","year":"2015","unstructured":"Chen J, Liu D, Zheng X, Zhao Q, Jiang J, Hu P. Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors\/inducers using physiologically based pharmacokinetic modeling. Expert Opin Drug Metab Toxicol. 2015;11(6):857\u201368.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"5","key":"412_CR28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00280-015-2862-0","volume":"76","author":"K Han","year":"2015","unstructured":"Han K, Jin JY, Marchand M, Eppler S, Choong N, Hack SP, et al. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemother Pharmacol. 2015;76(5):917\u201324.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"412_CR29","doi-asserted-by":"crossref","first-page":"e00156","DOI":"10.1002\/prp2.156","volume":"3","author":"J Jong de","year":"2015","unstructured":"de Jong J, Skee D, Murphy J, Sukbuntherng J, Hellemans P, Smit J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect. 2015;3(4):e00156.","journal-title":"Pharmacol Res Perspect."},{"issue":"2","key":"412_CR30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/FTD.0b013e31821160c4","volume":"33","author":"GV Bakken","year":"2011","unstructured":"Bakken GV, Rudberg I, Molden E, Refsum H, Hermann M. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit. 2011;33(2):222\u20136.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"412_CR31","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1208\/s12248-013-9530-2","volume":"15","author":"M Tod","year":"2013","unstructured":"Tod M, Nkoud-Mongo C, Gueyffier F. Impact of genetic polymorphism on drug\u2013drug interactions mediated by cytochromes: a general approach. AAPS J. 2013;15(4):1242\u201352.","journal-title":"AAPS J."},{"issue":"3","key":"412_CR32","first-page":"E439","volume":"18","author":"OA Linares","year":"2015","unstructured":"Linares OA, Fudin J, Boston RC, Daly AL. Integrating clinical pharmacokinetics, pharmacogenetics, and quantitative cytochrome P450 polymorphic gene drug\u2013drug interactions (DDIs). Pain Physician. 2015;18(3):E439\u201341.","journal-title":"Pain Physician"},{"key":"412_CR33","unstructured":"US Food and Drug Administration. Itraconazole (SPORANOX) clinical pharmacology and biopharmaceutics review: summary basis of approval. Silver Spring: US Food and Drug Administration; 1999. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/20-966_SPORANOX%20INJECTION%2010MG%20PER%20ML_BIOPHARMR.PDF . Accessed 5 May 2016."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0412-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0412-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0412-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0412-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T11:28:11Z","timestamp":1656588491000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0412-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,25]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["412"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0412-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,25]]}}}